Invivyd Appoints William Duke As New CFO
(RTTNews) - Biopharmaceutical company Invivyd, Inc. (IVVD) announced Tuesday the appointment of William Duke as Chief Financial Officer. Duke will lead Invivyd's financial strategy to support the company's continued growth.
Duke has more than 25 years of finance, accounting, and operations experience, including over a decade of senior leadership experience in the biotechnology industry.
Prior to joining Invivyd, Duke served as the CFO of Apexigen, Inc. and CFO of Kaleido Biosciences, Inc., where he led the successful completion of multiple financings.
Prior to Kaleido Biosciences, he was Chief Financial Officer of Pulmatrix, Inc., where he helped negotiate the company's first product partnership and led the successful completion of several public offerings.
Prior to that, he held senior financial leadership roles at Valeritas, Inc. and Genzyme Corp., where he helped in the sale of the company to Sanofi.
Invivyd Announces Positive 180-day Clinical Efficacy Data From CANOPY Phase 3 Trial Of Pemivibart
Major European Markets Close On Firm Note
Technology Stocks Shine; TSX Up Nearly 0.5%
U.S. Leading Economic Index Falls Much More Than Expected In August
Philly Fed Index Surges To Eight-Month High In September
Bank Of England Holds Key Rate; Slows Quantitative Tightening
U.S. Weekly Jobless Claims Pull Back Off Nearly Four-Year High
